For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

Retatrutide: origin, structure and research history

Research Library › Incretin & Amylin

Retatrutide is an investigational single peptide, conjugated to a fatty diacid, that was designed to activate three hormone receptors: GIP, GLP-1 and glucagon. It was discovered at Eli Lilly under the code LY3437943 and described in a 2022 discovery paper. As of October 2026 it is not approved by the FDA or any other regulator; Lilly plans to file with the FDA in the first quarter of 2027, and the FDA has said federal law bars its use in compounding.

Key facts

TypeInvestigational synthetic peptide conjugated to a fatty diacid moiety
Other namesLY3437943
Developed byEli Lilly and Company, Indianapolis, USA
First described2022, discovery-to-proof-of-concept paper in Cell Metabolism
Designed targetTriple agonist of the GIP, GLP-1 and glucagon receptors
Regulatory status (Oct 2026)Not FDA-approved; Phase 3 (TRIUMPH program) ongoing; Lilly plans US submission in Q1 2027; FDA says it cannot lawfully be compounded

Who developed it

Retatrutide was discovered and developed by Eli Lilly and Company. Lilly scientists described the molecule, then known as LY3437943, in a 2022 Cell Metabolism paper covering its path from discovery to early clinical proof of concept [1].

Lilly remains the developer and sponsors the Phase 3 trials, which it groups under the TRIUMPH name for obesity-related research and TRANSCEND for type 2 diabetes [2, 3].

Structure and design

Retatrutide is a single peptide conjugated to a fatty diacid moiety [4]. Lilly describes it as a first-in-class triple hormone receptor agonist, designed to act at the receptors for GIP, GLP-1 and glucagon within one molecule [2].

It extends a line of Lilly research on multi-receptor incretin molecules. Tirzepatide was designed to act at two of these receptors, GIP and GLP-1. Retatrutide adds activity at the glucagon receptor, a design that researchers proposed for study in metabolic disease programs [1, 2]. Any mechanism in people remains under clinical investigation.

Research history

  • 2022: Lilly publishes the discovery of LY3437943 [1]
  • June 2023: Phase 2 trial in obesity published in the New England Journal of Medicine [4]
  • December 2025: Lilly reports the first completed Phase 3 trial, TRIUMPH-4 [5]
  • July 2026: Lilly reports TRIUMPH-2 and TRIUMPH-3, completing the initial TRIUMPH registration program of four global trials with more than 5,800 participants [2]
  • August 2026: Lilly states it plans a US submission in the first quarter of 2027 [6]

Lilly has said further Phase 3 trials are underway in other research areas, including chronic kidney disease and fatty liver disease [3].

Regulatory status as of October 2026

Retatrutide is not approved by the FDA or any other regulatory agency. Lilly states that it is available only to participants in Lilly-sponsored clinical trials [3]. In August 2026 the company said it planned to file with the FDA in the first quarter of 2027, for indications in obesity and related conditions [6].

The FDA states that federal law bars the use of retatrutide in compounding, because it is not a component of any FDA-approved drug. The agency has also warned telehealth companies, ingredient distributors and outsourcing facilities over retatrutide [7]. It has warned firms selling retatrutide labeled “for research purposes” or “not for human consumption” [7]. In a March 2026 warning letter, the FDA said a “Research Use Only” label did not change its finding that retatrutide sold online was an unapproved new drug [8]. Lilly has publicly warned that illicit products sold as retatrutide may contain unknown ingredients or impurities [3].

About this reference page

Kalibra Labs does not currently supply Retatrutide. This page is published as a neutral scientific and regulatory reference. Browse the Incretin & Amylin guide or the FDA Peptide Regulatory Tracker.

Frequently asked questions

Is retatrutide FDA approved?

No. As of October 2026 retatrutide is investigational and not approved anywhere; Lilly plans a US submission in the first quarter of 2027 [3, 6].

Who makes retatrutide?

Retatrutide was discovered and is being developed by Eli Lilly and Company under the code LY3437943 [1].

Why is retatrutide called a triple agonist?

It was designed as one molecule that activates three receptors: those for GIP, GLP-1 and glucagon [2].

How is retatrutide related to tirzepatide?

Both were developed by Eli Lilly. Tirzepatide was designed to act at the GIP and GLP-1 receptors, while retatrutide was designed to add the glucagon receptor as a third target [1, 2].

Can retatrutide be compounded?

No. The FDA states that federal law bars compounding with retatrutide because it is not part of any FDA-approved drug [7].

Sources

  1. Coskun T, Urva S, Roell WC, et al., Milicevic Z. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234–1247.e9. doi:10.1016/j.cmet.2022.07.013. Link
  2. Eli Lilly and Company. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials (TRIUMPH-2, TRIUMPH-3). Press release, 23 Jul 2026. Link
  3. Eli Lilly and Company. What to know about retatrutide. Lilly news story, Sep/Oct 2026. Link
  4. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514–526. doi:10.1056/NEJMoa2301972. Link
  5. Eli Lilly and Company. Press release on TRIUMPH-4 (NCT05931367), first Phase 3 trial of retatrutide. 11 Dec 2025. Link
  6. Eli Lilly and Company. Lilly reports second-quarter 2026 financial results. Press release, 5 Aug 2026. Link
  7. U.S. FDA. FDA's concerns with unapproved GLP-1 drugs used for weight loss (updated 1 Oct 2026). Link
  8. U.S. FDA. Warning letter to Gram Peptides, MARCS-CMS 721806, 31 Mar 2026. Link

Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.

Kalibra Labs does not supply this compound. This page is a scientific, historical and regulatory reference only; it is not medical advice and makes no claim about use in people or animals.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top